The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
Open accessAbstract
Androgen deprivation therapy remains a critical component of treatment for men with advanced prostate cancer, and data support its use in metastatic disease and in conjunction with surgery or radiation in specific settings. Alternatives to standard androgen deprivation therapy, such as intermittent androgen suppression and estrogen therapy, hold the potential to improve toxicity profiles while maintaining clinical benefit. Current androgen deprivation strategies seem to incompletely suppress androgen levels and androgen-receptor-mediated effects at the tissue level. Advances in the understanding of mechanisms that contribute to castration-resistant prostate cancer are leading to rationally designed therapies targeting androgen metabolism and the androgen receptor. The results of large trials investigating the optimization of primary androgen deprivation therapy, including evaluation of intermittent androgen suppression and phase III studies of novel androgen synthesis inhibitors, such as abiraterone acetate, are eagerly awaited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Huggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,855
Kamangar, F., Dores, G. M., & Anderson, W. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2308 · Cited by 3,434
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09408-4 · Cited by 1,686
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Self-citationMessing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., & Trump, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412401 · Cited by 1,191
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9749 · Cited by 903
Messing, E. M., Manola, J., Yao, J., Kiernan, M., Crawford, D., Wilding, G., di'SantAgnese, P. A., & Trump, D. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70700-8 · Cited by 893
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials
(2000) · The Lancet · doi:10.1016/s0140-6736(00)02163-2 · Cited by 819
Pilepich, M. V., Winter, K., John, M. J., Mesic, J. B., Sause, W., Rubin, P., Lawton, C., Machtay, M., & Grignon, D. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01579-6 · Cited by 772
D'Amico, A. V., Manola, J., Loffredo, M., Renshaw, A. A., DellaCroce, A., & Kantoff, P. W. (2004) · JAMA · doi:10.1001/jama.292.7.821 · Cited by 767
Locke, J. A., Guns, E. S., Lubik, A. A., Adomat, H. H., Hendy, S. C., Wood, C. A., Ettinger, S. L., Gleave, M. E., & Nelson, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5997 · Cited by 747
The Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675
Klotz, L. H., BOCCON-GIBOD, L., Shore, N. D., Andreou, C., Persson, B., Cantor, P., Jensen, J.-K., Olesen, T. K., & Schröder, F. H. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.08183.x · Cited by 666
(1997) · British Journal of Urology · doi:10.1046/j.1464-410x.1997.d01-6840.x · Cited by 654
Loblaw, D. A., Virgo, K. S., Nam, R., Somerfield, M. R., Ben-Josef, E., Mendelson, D. S., Middleton, R., Sharp, S. A., Smith, T. J., Talcott, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1949 · Cited by 555
Adib, R., Anderson, J., Ashken, M. H., Baumber, C. D., CRA, B. D., BEYNON, L. L., Blaxland, J. W., Boag, V., Bolger, J., Boreham, J., et al. (1997) · Kent Academic Repository (University of Kent) · Cited by 551
Mostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3332 · Cited by 529
Self-citationMechanisms Underlying the Development of Androgen-Independent Prostate Cancer
Pienta, K. J., & Bradley, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0067 · Cited by 430
Denham, J. W., Steigler, A., Lamb, D. S., Joseph, D., Mameghan, H., Turner, S., Matthews, J., Franklin, I., Atkinson, C., North, J., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70348-x · Cited by 375
Lawton, C. A., Winter, K., Murray, K., Machtay, M., Mesic, J. B., Hanks, G. E., Coughlin, C. T., & Pilepich, M. V. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)01516-9 · Cited by 374
COOPERBERG, M. R., BROERING, J. M., LITWIN, M. S., LUBECK, D. P., MEHTA, S. S., HENNING, J. M., CARROLL, P. R., & the CaPSURE INVESTIGATORS (2004) · Journal of Urology · doi:10.1097/01.ju.0000107247.81471.06 · Cited by 340
Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer
Lu-Yao, G. L. (2008) · JAMA · doi:10.1001/jama.300.2.173 · Cited by 315
Byar, D. P., & Corle, D. K. (1989) · Journal of Urology · doi:10.1016/s0022-5347(17)41100-1 · Cited by 303
Agus, D. B., Cordon-Cardo, C., Fox, W., Drobnjak, M., Koff, A., Golde, D. W., & Scher, H. I. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.21.1869 · Cited by 248
Dillard, P. R., Lin, M.-F., & Khan, S. A. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.013 · Cited by 225
Ricke, W. A., McPherson, S. J., Bianco, J. J., Cunha, G. R., Wang, Y., & Risbridger, G. P. (2008) · The FASEB Journal · doi:10.1096/fj.07-9526com · Cited by 213
Modulation of Androgen Receptor Activation Function 2 by Testosterone and Dihydrotestosterone
Askew, E. B., Gampe, R. T., Stanley, T. B., Faggart, J. L., & Wilson, E. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703268200 · Cited by 210
Drug Insight: role of the androgen receptor in the development and progression of prostate cancer
Taplin, M.-E. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0765 · Cited by 197
Management of Complications of Prostate Cancer Treatment
Michaelson, M. D., Cotter, S. E., Gargollo, P. C., Zietman, A. L., Dahl, D. M., & Smith, M. R. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2008.0002 · Cited by 196
Sato, N., Gleave, M. E., Bruchovsky, N., Rennie, P. S., Goldenberg, S. L., Lange, P. H., & Sullivan, L. D. (1996) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(96)00018-0 · Cited by 184
Vasaitis, T. S., Belosay, A., Schayowitz, A., Khandelwal, A., Chopra, P., Gediya, L. K., Guo, Z., Fang, H., Njar, V. C. O., & Brodie, A. M. H. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0230 · Cited by 148
Adrenal Androgens and Intracrinology
Labrie, F. (2004) · Seminars in Reproductive Medicine · doi:10.1055/s-2004-861547 · Cited by 145
Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study
Higano, C. S., Ellis, W., Russell, K., & Lange, P. H. (1996) · Urology · doi:10.1016/s0090-4295(96)00381-0 · Cited by 141
Mostaghel, E. A., & Nelson, P. S. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.01.003 · Cited by 141
Self-citationByar, D. P., & Corle, D. K. (1988) · PubMed · Cited by 139
CYP17 inhibition as a hormonal strategy for prostate cancer
Reid, A. H. M., Attard, G., Barrie, E., & Bono, J. S. D. (2008) · Nature Clinical Practice Urology · doi:10.1038/ncpuro1237 · Cited by 119
Kraus, S., Gioeli, D., Vomastek, T., Gordon, V., & Weber, M. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0596 · Cited by 118
The role of diethylstilbestrol in the treatment of prostate cancer
Malkowicz, S. B. (2001) · Urology · doi:10.1016/s0090-4295(01)01252-3 · Cited by 114
Schröder, F. H., Kurth, K., Fosså, S. D., Hoekstra, W. J., Karthaus, P., Debois, M., & Collette, L. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000135742.13171.d2 · Cited by 100
Ten-Year Survival in Patients with Metastatic Prostate Cancer
Tangen, C. M., Faulkner, J. R., Crawford, E. D., Thompson, I. M., Hirano, D., Eisenberger, M. A., & Hussain, M. (2003) · Clinical Prostate Cancer · doi:10.3816/cgc.2003.n.011 · Cited by 98
Prostate Specific Antigen Recurrence After Definitive Therapy
Freedland, S. J., & Moul, J. W. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.01.137 · Cited by 91
Higano, C. S., Shields, A. T., Wood, N., Brown, J. E., & Tangen, C. M. (2004) · Urology · doi:10.1016/j.urology.2004.07.019 · Cited by 91
The role of testosterone in the pathogenesis of prostate cancer
Imamoto, T., Suzuki, H., Yano, M., Kawamura, K., Kamiya, N., Araki, K., Komiya, A., Nihei, N., Naya, Y., & Ichikawa, T. (2008) · International Journal of Urology · doi:10.1111/j.1442-2042.2008.02074.x · Cited by 79
Miller, K., Steiner, U., Lingnau, A., Keilholz, U., Witzsch, U. H. F., Haider, A., Wachter, U., Rüssel, C., & Altwein, J. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.5015 · Cited by 77
Montironi, R., Magi‐Galluzzi, C., Muzzonigro, G., Prete, E., Polito, M., & Fabris, G. (1994) · Journal of Clinical Pathology · doi:10.1136/jcp.47.10.906 · Cited by 77
Ohlson, N., Wikström, P., Stattin, P. E., & Bergh, A. R. J. (2004) · The Prostate · doi:10.1002/pros.20139 · Cited by 75
Pravettoni, A., Mornati, O., Martini, P. G. V., Marino, M., Colciago, A., Celotti, F., Motta, M., & Negri‐Cesi, P. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.08.008 · Cited by 71
The role of intermittent androgen deprivation in prostate cancer
BOCCON-GIBOD, L., Hammerer, P. G., Stephan Madersbacher, A., Mottet, N., Prayer‐Galetti, T., & Tunn, U. W. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07053.x · Cited by 68
D'Amico, A. V., Chen, M., Renshaw, A. A., Loffredo, B., & Kantoff, P. W. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9699 · Cited by 61
Intermittent androgen blockade should be regarded as standard therapy in prostate cancer
Šeruga, B., & Tannock, I. F. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1180 · Cited by 57
Endocrine complications of androgen-deprivation therapy in men with prostate cancer.
Harle, L., Maggio, M., Shahani, S., Braga‐Basaria, M., & Basaria, S. S. (2006) · PubMed · Cited by 55
Phase II study of transdermal estradiol in androgen‐independent prostate carcinoma
Bland, L. B., Garzotto, M. G., DeLoughery, T. G., Ryan, C. W., Schuff, K. G., Wersinger, E. M., Lemmon, D., & Beer, T. M. (2005) · Cancer · doi:10.1002/cncr.20857 · Cited by 49
Kitahara, S., Umeda, H., YANO, M., Koga, F., Sumi, S., Moriguchi, H., Hosoya, Y., Honda, M., & Yoshida, K. (1999) · Endocrine Journal · doi:10.1507/endocrj.46.659 · Cited by 43
Early effects of pharmacological androgen deprivation in human prostate cancer
Mercader, M., Sengupta, S., Bodner, B. K., Manecke, R. G., Cosar, E. F., Moser, M. T., Ballman, K. V., Wojcik, E. M., & Kwon, E. D. (2006) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.06538.x · Cited by 34
Purnell, J. Q., Bland, L. B., Garzotto, M., Lemmon, D., Wersinger, E. M., Ryan, C. W., Brunzell, J. D., & Beer, T. M. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500276-jlr200 · Cited by 28
Liu, J., Geller, J., ALBERT, J. D., & Kirshner, M. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-61-1-129 · Cited by 28
Scher, H. I., Beer, T. M., Higano, C. S., Danila, D. C., Montgomery, B., Shelkey, J., Hirmand, M., Hung, D. T., & Sawyers, C. L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5006 · Cited by 26
Self-citationCurrent Thoughts on the Role of the Androgen Receptor and Prostate Cancer Progression
Setlur, S. R., & Rubin, M. A. (2005) · Advances in Anatomic Pathology · doi:10.1097/01.pap.0000184179.50672.f7 · Cited by 24
Cited by
The evolutionary history of lethal metastatic prostate cancer
ICGC Prostate UK Group, Gundem, G., Van Loo, P., Kremeyer, B., Alexandrov, L. B., Tubio, J. M. C., Papaemmanuil, E., Brewer, D. S., Kallio, H. M. L., Högnäs, G., et al. (2015) · Nature · doi:10.1038/nature14347 · Cited by 1,388
Androgen receptor: structure, role in prostate cancer and drug discovery
Tan, M. E., Li, J., Xu, H. E., Melcher, K., & Yong, E.-L. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.18 · Cited by 943
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Asangani, I. A., Dommeti, V. L., Wang, X., Malik, R., Cieslik, M., Yang, R., Escara-Wilke, J., Wilder-Romans, K., Dhanireddy, S., Engelke, C., et al. (2014) · Nature · doi:10.1038/nature13229 · Cited by 927
Karantanos, T., Corn, P. G., & Thompson, T. C. (2013) · Oncogene · doi:10.1038/onc.2013.206 · Cited by 866
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852
Metadata
- Authors
- Harris, W. P., Mostaghel, E. A., Nelson, P. S., & Montgomery, B.
- Venue
- Nature Clinical Practice Urology
- Published
- 2009-02
- Volume
- 6
- Issue
- 2
- Pages
- 76-85
- ISSN
- 1743-4270 (ISSN-L)
- 1743-4289
- OpenAlex
- W2005958584
- Cited by
- 877
- References
- 63
- FWCI
- 18.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.